Martínez López, Joaquín
Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations. [artículo] - Leukemia research reports, 2015 - 4(2):64-9.
Formato Vancouver:
López A, Mateos MV, Oriol A, Valero M, Martínez J, Lorenzo JI et al. Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations. Leuk Res Rep. 2015 Sep 24;4(2):64-9.
PMID: 26500850
PMC4588395
Contiene 23 referencias
We report the characteristics of relapse, treatment response, and outcomes of 145 elderly patients with multiple myeloma in first relapse after front-line treatment with VMP or VTP. Reappearance of CRAB symptoms (113 patients) and more aggressive forms of disease (32 patients) were the most common patterns of relapse. After second-line therapy, 75 (51.7%) patients achieved at partial response and 16 (11%) complete response (CR). Overall survival was longer among patients receiving VMP as front-line induction (21.4 vs. 14.4 months, P=0.037), in patients achieving CR (28.3 vs. 14.8 months; P=0.04), and in patients without aggressive relapse (28.6 vs. 7.6 months; P=0.0007).
Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations. [artículo] - Leukemia research reports, 2015 - 4(2):64-9.
Formato Vancouver:
López A, Mateos MV, Oriol A, Valero M, Martínez J, Lorenzo JI et al. Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations. Leuk Res Rep. 2015 Sep 24;4(2):64-9.
PMID: 26500850
PMC4588395
Contiene 23 referencias
We report the characteristics of relapse, treatment response, and outcomes of 145 elderly patients with multiple myeloma in first relapse after front-line treatment with VMP or VTP. Reappearance of CRAB symptoms (113 patients) and more aggressive forms of disease (32 patients) were the most common patterns of relapse. After second-line therapy, 75 (51.7%) patients achieved at partial response and 16 (11%) complete response (CR). Overall survival was longer among patients receiving VMP as front-line induction (21.4 vs. 14.4 months, P=0.037), in patients achieving CR (28.3 vs. 14.8 months; P=0.04), and in patients without aggressive relapse (28.6 vs. 7.6 months; P=0.0007).
